Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rozanolixizumab in adult participants with LGI1 autoimmune encephalitis
2019-004778-25Phase 2Terminated
- Sponsor
- UCB
- Start
- Jan 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Autoimmune Encephalitis (AE) comparing Rozanolixizumab with Placebo (2 arms). Primary endpoint: Proportion of seizure-free participants at end of treatment. Started Jan 2021; status: terminated.
02
Drugs
rozanolixizumab
03
Conditions
Autoimmune Encephalitis (AE)
Beyond the preview
Go deeper on 2019-004778-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004778-25.